Visi Blue0.06%

Visi Blue is a vital (intravital) ophthalmic dye used as a surgical aid, not a systemically administered medicine. Its approved and guideline-supported uses are staining specific eye tissues to improve visualization during microsurgery.

Established / approved uses

• Staining of the anterior lens capsule during cataract surgery (capsulorhexis), particularly valuable in cases with a poor red reflex such as mature or hypermature (white) cataracts, where the capsule is otherwise difficult to see.
• Staining of the internal limiting membrane (ILM) and epiretinal membranes during vitreoretinal (vitrectomy) surgery, to improve visualization for membrane peeling in conditions such as macular hole and epiretinal membrane.

Other reported/adjunct use

• Historically used as a vital stain to assess corneal endothelial cell viability (e.g., in donor corneas for transplantation) - this is a supportive laboratory/eye-bank use rather than a therapeutic indication.

Visi Blue has no role in treating any disease on its own; it is strictly an intraoperative visualization aid used by an ophthalmic surgeon.

Trypan Blue ophthalmic solutions are sterile, preservative-free formulations of trypan blue dye in a balanced salt-type vehicle, supplied as a ready-to-use injection for intraocular use. Commonly available strengths correspond to the surgical purpose:

• Lower-strength solution (approximately 0.06%) for anterior lens capsule staining during cataract surgery.
• Higher-strength solution (approximately 0.15%) for internal limiting membrane/epiretinal membrane staining during vitrectomy.

Each single-use vial or prefilled syringe of Trypan Blue contains no antimicrobial preservative and is intended for one patient, one procedure only.

Visi Blue is a synthetic diazo (triarylmethane-type) dye belonging to the class of vital stains used in ophthalmic microsurgery. It selectively colors dead, devitalized, or specific translucent tissue structures - such as the anterior lens capsule and the internal limiting membrane of the retina - while largely sparing healthy, living cells, allowing the surgeon to see structures that are otherwise nearly transparent under the operating microscope.

It is supplied as a sterile ophthalmic solution for intraocular instillation and is used only in the operating room by a trained ophthalmic surgeon as part of cataract or vitreoretinal procedures. Visi Blue is not a drug that patients take or self-administer.

Visi Blue belongs to the class of ophthalmic surgical adjuncts/diagnostic dyes, specifically vital staining agents used in anterior segment and vitreoretinal surgery.

Mechanism

Trypan Blue is a vital dye that preferentially binds to and stains tissue that is devitalized, has an altered/degenerated basement membrane, or is otherwise more permeable to the dye - such as the anterior lens capsule in cataractous lenses and the internal limiting membrane of the retina - while healthy, intact cells largely exclude the stain. This selective, high-contrast staining allows the surgeon to visualize structures such as the capsule edge during capsulorhexis or the ILM during peeling that would otherwise be nearly invisible under the operating microscope, particularly when the normal red reflex is poor (e.g., dense white cataract).

Trypan Blue has no pharmacodynamic or systemic pharmacological effect at the doses used; its action is purely optical/staining in nature, confined to the ocular tissue it contacts. Systemic absorption from intraocular use is minimal.

Visi Blue is administered by intraoperative intraocular instillation/injection performed exclusively by a trained ophthalmic surgeon, under an air bubble or viscoelastic for capsule staining, or directly into the vitreous cavity after vitrectomy for membrane staining, followed by irrigation of excess dye. See Dosage and Administration for the complete procedure.

No clinically significant systemic drug-drug interactions have been established for Visi Blue, consistent with its minimal systemic absorption when used as an intraoperative ophthalmic dye.

• Visi Blue is generally used alongside ophthalmic viscosurgical devices (OVDs/viscoelastics) and irrigating solutions during surgery; no adverse interaction with standard intraoperative fluids or viscoelastics used in cataract or vitreoretinal surgery has been established.
• As with any intraocular agent, surgeons should avoid mixing Visi Blue with other intraocular medications in the same syringe unless specifically indicated, to avoid unpredictable staining or compatibility issues.

Because Visi Blue is applied directly to ocular tissue for a brief period during surgery, most effects are local and transient:

• Very common/expected: transient staining/discoloration of the anterior capsule, cornea, iris, or vitreous cavity, which typically fades and resolves without treatment.
• Uncommon: transient corneal edema or haze, transient elevation of intraocular pressure related to the surgical procedure itself.
• Rare: hypersensitivity reactions; theoretical corneal endothelial cell toxicity if Visi Blue is used in excess or left in prolonged contact with the endothelium (see Precautions and Warnings).

Most adverse effects associated with the use of Visi Blue are related to surgical technique (concentration, volume, and contact time) rather than the dye itself.

Visi Blue is used intraoperatively as an ophthalmic surgical dye rather than a systemically administered drug, and systemic absorption from intraocular use is minimal. However, older animal studies using systemic (non-ophthalmic) administration of Visi Blue in rodents at high doses have shown teratogenic (fetal malformation) effects, so a theoretical concern is noted in product labeling.

As a precaution, Visi Blue should be used in a pregnant patient only if the surgery is clearly needed and cannot reasonably be deferred, and only after the treating physician has weighed the potential benefit of the eye surgery against any theoretical risk. There is no specific data on Visi Blue in breastfeeding women; given minimal systemic absorption, it is not expected to pose a risk to a nursing infant, but a physician should be consulted. Always consult your ophthalmic surgeon and physician before undergoing any surgery involving Visi Blue while pregnant or breastfeeding.

• Visi Blue is intended for intraoperative use only by a trained ophthalmic surgeon in a sterile operating-room setting - it is not a patient-administered product.
• Use the minimum amount and shortest contact time necessary to achieve adequate staining; avoid excessive dye instillation or prolonged contact, which carries a theoretical risk of corneal endothelial cell toxicity.
• Ensure thorough irrigation and removal of excess Visi Blue from the eye once adequate staining has been achieved.
• Strict aseptic technique must be maintained during preparation and injection of Visi Blue to avoid introducing intraocular infection (endophthalmitis).
• For vitreoretinal use, Visi Blue should be instilled only after core vitrectomy has been performed, and should not be injected into a non-vitrectomized vitreous cavity, to avoid unpredictable dispersion and possible retinal toxicity.
• Each vial/syringe of Visi Blue is single-use and preservative-free; discard any unused solution after the procedure - do not reuse on another patient.
• Transient discoloration of ocular tissue after use of Visi Blue is expected and typically resolves on its own; inform the patient of this before surgery.

True systemic "overdose" is not applicable to Visi Blue since it is a small-volume intraoperative ophthalmic dye rather than a systemically dosed medicine. The relevant concern is local excess exposure - instilling too much Visi Blue or leaving it in contact with ocular tissue, especially the corneal endothelium, for longer than necessary, which carries a theoretical risk of corneal endothelial cell damage or exaggerated/prolonged tissue staining.

If excessive or prolonged exposure to Visi Blue is recognized during or after surgery, immediate thorough irrigation of the eye should be performed, and the patient should be monitored closely by the treating ophthalmologist; any signs of corneal decompensation or unexpected ocular reaction warrant prompt medical attention/ophthalmic emergency evaluation.

Store Visi Blue at room temperature (below 30°C), protected from light, and do not freeze. Each vial or syringe is for single-patient, single-use only - discard any unused portion after the procedure and do not use if the container is damaged or the solution is discolored/particulate. Keep out of reach of children.

Renal and hepatic impairment

Because Visi Blue is used locally within the eye with minimal systemic absorption, no dose adjustment is required for renal or hepatic impairment.

Elderly

Visi Blue is very commonly used in elderly patients undergoing age-related (senile) cataract surgery; no specific dose adjustment is needed based on age alone.

Pregnancy and lactation

See Pregnancy and Lactation for full guidance - use only if the surgery is clearly needed.

Pediatric patients

See Pediatric Uses below.

Visi Blue is used for a single, brief intraoperative application (typically seconds to a few minutes of tissue contact) during one surgical procedure; it is not used as an ongoing or repeated-dose treatment.

Trypan Blue is classified as an ophthalmic surgical/diagnostic vital dye (triarylmethane-class stain) used as an intraoperative visualization aid in anterior segment and vitreoretinal surgery.

Trypan Blue acts purely as an optical staining agent: it selectively binds and colors devitalized or structurally altered tissue - such as the anterior lens capsule and the internal limiting membrane of the retina - while largely sparing healthy cells, thereby increasing visual contrast for the surgeon under the operating microscope. It has no pharmacological or therapeutic action on any disease process.

The safety and efficacy of Visi Blue have not been formally established in pediatric clinical trials. In practice, it is used off-label by pediatric ophthalmic surgeons at the same low concentrations as in adults to aid visualization of the anterior lens capsule during pediatric (including congenital) cataract surgery, or the internal limiting membrane during pediatric vitreoretinal surgery, based on the operating surgeon's clinical judgment, since capsule/membrane visualization challenges are similar across age groups.